Acquired haemophilia A in southern Switzerland from 2013 to 2019: a case series

AIMS OF THE STUDY: Acquired haemophilia A is a rare disease with an annual incidence of 1.48 per million. Based on clinical observations, we suspect a higher incidence in southern Switzerland, and aimed at providing local epidemiological data, and clinical information regarding diagnosis, treatment and outcome in our region. METHODS: All adult patients with acquired haemophilia A treated between 2013 and 2019 in our facility were included in the present retrospective analysis. RESULTS: We treated 11 patients with acquired haemophilia A between 2013 and 2019, resulting in an annual incidence of 4.5 per million (95% confidence interval [CI] 0–9.0). Median delay from first symptoms to diagnosis was 4.5 days, and the median age at diagnosis was 79 years (range 23–87). Possible causative conditions were: pregnancy (n = 1), polyarteritis nodosa (n = 1), myelodysplastic syndrome (n = 1), chronic human immunodeficiency virus (HIV) (n = 1), and HIV postexposure prophylaxis (n = 1). In five patients no underlying or associated condition was identified. Median activated partial thromboplastin time (aPTT)) at baseline was 79 seconds (65–117; ref. value <38 sec), and FVIII:C 2.15% (<1–3.75%). A FVIII:C <1% was present in 4/10 patients. Median FVIII-inhibitor titre was 10.3 BU/ml (2.4–75.0 BU/ml). All patients had bleeding symptoms, 5/10 patients had major bleedings, and 7/10 patients were treated with bypassing agents. All patients received corticosteroids; 7/10 patients received immunosuppressive combination therapy. FVIII levels of ≥50% were achieved after a median of 40 days (8–62). One patient had a severe immunosuppressive therapy-related infection. An 87-years-old woman died for reasons not related to acquired haemophilia A or immunosuppressive therapy. CONCLUSIONS: Acquired haemophilia A is a rare disease, but manageable despite the advanced patient age and comorbidities. Its incidence in Southern Switzerland is higher than previously suspected.

[1]  J. Oldenburg,et al.  Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID‐19 vaccines , 2022, Journal of Thrombosis and Haemostasis.

[2]  W. Korte,et al.  The statistical risk of diagnosing coincidental acquired hemophilia A following anti‐SARS‐CoV‐2 vaccination , 2021, Journal of Thrombosis and Haemostasis.

[3]  S. Lacroix-Desmazes,et al.  Acquired Hemophilia A in IgG4-Related Disease: Case Report, Immunopathogenic Study, and Review of the Literature , 2020, Frontiers in Immunology.

[4]  L. Alberio,et al.  Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. , 2020, Swiss medical weekly.

[5]  P. Knöbl,et al.  Should emicizumab be used in patients with acquired hemophilia A? , 2020, Journal of thrombosis and haemostasis : JTH.

[6]  A. Tiede,et al.  The rising incidence of acquired haemophilia A in Germany , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  A. Tiede,et al.  Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study , 2020, Annals of Hematology.

[8]  A. Tiede,et al.  Acquired bleeding disorders , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  P. Giangrande,et al.  International recommendations on the diagnosis and treatment of acquired hemophilia A , 2020, Haematologica.

[10]  P. Knöbl,et al.  Bleeding and Response to Hemostatic Therapy in Acquired Hemophilia A (AHA): Results from the GTH-AH 01/2010 Study. , 2020, Blood.

[11]  J. Goetze,et al.  Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini‐review , 2020, European journal of haematology.

[12]  C. Königs,et al.  Cross‐reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH‐AH 01/2010 Study , 2020, Journal of thrombosis and haemostasis : JTH.

[13]  P. Giangrande,et al.  Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  J. Shaw,et al.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2019, Diabetes research and clinical practice.

[15]  A. Pottegård,et al.  Use of prescription drugs in the older adult population—a nationwide pharmacoepidemiological study , 2019, European Journal of Clinical Pharmacology.

[16]  A. Bonnefoy,et al.  Relapse pattern and long‐term outcomes in subjects with acquired haemophilia A , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  C. Santoro,et al.  Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry. , 2019, Thrombosis research.

[18]  R. Nisenbaum,et al.  Retrospective review of Acquired Haemophilia A from the largest Canadian Haemophilia treatment centre , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  C. Königs,et al.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. , 2017, Blood.

[20]  Y. Komiyama,et al.  New formulas for mixing test to discriminate between lupus anticoagulant and acquired hemophilia A. , 2016, Thrombosis research.

[21]  A. Koch,et al.  Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. , 2016, Blood.

[22]  W. Tsay,et al.  A study of 65 patients with acquired hemophilia A in Taiwan. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[23]  E. Gomperts,et al.  Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  R. Greil,et al.  Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. , 2015, Blood.

[25]  J. Goudemand,et al.  Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  F. Pellegrini,et al.  Pregnancy‐associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry , 2012, BJOG : an international journal of obstetrics and gynaecology.

[27]  C. Granier,et al.  The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII , 2012, Journal of thrombosis and haemostasis : JTH.

[28]  F. Pellegrini,et al.  Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). , 2012, Blood.

[29]  F. Pellegrini,et al.  Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. , 2012, Blood.

[30]  J. Esser,et al.  Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) , 2012, Journal of thrombosis and haemostasis : JTH.

[31]  J. Oldenburg,et al.  Genetic markers in acquired haemophilia , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[32]  A. Ganser,et al.  Acquired haemophilia caused by non-haemophilic factor VIII gene variants , 2010, Annals of Hematology.

[33]  T. Baglin,et al.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. , 2007, Blood.

[34]  M. Reding Immunological aspects of inhibitor development , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[35]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[36]  J. Delgado,et al.  Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors , 2003, British journal of haematology.

[37]  C. Kitchens,et al.  Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. , 1987, Archives of internal medicine.

[38]  M. Modan,et al.  Detection and Quantitative Evaluation of Lupus Circulating Anticoagulant Activity , 1987, Thrombosis and Haemostasis.

[39]  K. Lechner,et al.  A Survey of 215 Non-Hemophilic Patients with Inhibitors to Factor VIII , 1981, Thrombosis and Haemostasis.